Karolina Englert

Dr. Karolina Englert

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2023 in Medicina
Verified
Journal Article
Open access
PDF file
KEKarolina Englert
Karolina Englert
GDGrzegorz Dyduch
Grzegorz Dyduch
AKAgata Kłosowicz
Agata Kłosowicz
MSMagdalena Spałkowska
Magdalena Spałkowska
AJAndrzej Jaworek
Andrzej Jaworek
AWAnna B Wojas-Pelc
Anna B Wojas-Pelc
Background and Objectives: Cutaneous lupus erythematosus (CLE) presents clinically heterogeneous manifestations, partially explained by the different expression of Toll-like receptors (TLRs) type 8 and 9, located to endosomal compartments where they are poised to recognize microbial nucleic acids. This disease is empirically treated with hydroxychloroquine (HCQ), which is hallmarked with a safe and effective profile, but induces a slow and sometimes clinically insufficient therapeutic response. Currently, no biomarkers predictive of response are validated or even proposed in the scientific literature. We aimed to evaluate endosomal TLR type 7, 8 and 9 as predictive biomarkers of HCQ efficacy. Materials and Methods: We conducted a case–control study comparing CLE patients retrospectively assigned to three subgroups based on 3–6-month Cutaneous LE Disease Area and Severity Index (CLASI) reduction upon treatment with HCQ (I = 80%). Before HCQ, lesional skin specimens were collected in untreated CLE and through immunohistochemistry; TLR-7, -8 and -9 expression was evaluated in the epidermis and the lymphocytic infiltrate was evaluated in the dermis. Results: Sixty-six lesional skin biopsies were compared with healthy controls. CLE patients displayed lower epidermal expression of total TLR 8 and 9 as well as infiltrating TLR-8, TLR9 + lymphocytes compared to controls. High HCQ responders differed from low responders for TLR-9 positivity (high vs. low) and for the lymphocytic dermal infiltrate (high vs. low). Conclusions: TLR9 could be envisaged as a possible biomarker to predict HCQ response level and dosage in CLE patients.

1 January 2020 in Advances in Dermatology and Allergology
Verified
Journal Article
Open access
KEKarolina Englert
Karolina Englert
AKAgata Kłosowicz
Agata Kłosowicz
BGBarbara Grześkowiak
Barbara Grześkowiak
AWAnna Wojas-Pelc
Anna Wojas-Pelc